SCHEMBL2777368

SCHEMBL2777368

O=CNC(C(=O)O)c1ccccc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 1/20 0.52
SRC P12931 2/20 0.46
OPRK1 P41145 1/20 0.46
LMNA P02545 2/20 0.45
MAPK1 P28482 1/20 0.45
HDAC4 P56524 2/20 0.44
HDAC1 Q13547 2/20 0.44
HDAC7 Q8WUI4 2/20 0.44
HDAC2 Q92769 2/20 0.44
HDAC8 Q9BY41 2/20 0.44
HDAC6 Q9UBN7 2/20 0.44
HDAC9 Q9UKV0 2/20 0.44
HDAC5 Q9UQL6 2/20 0.44
KMT2A Q03164 1/20 0.44
FPR2 P25090 1/20 0.44
NAALAD2 Q9Y3Q0 1/20 0.42
EPHX1 P07099 1/20 0.42
CA1 P00915 1/20 0.41
CA2 P00918 1/20 0.41
HDAC3 O15379 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14871996 1.00 CYP2D6 (0.52) CYP2D6SRCOPRK1LMNAMAPK1
SCHEMBL2478440 1.00 CYP2D6 (0.52) CYP2D6SRCOPRK1LMNAMAPK1
SCHEMBL9450258 0.85 OPRK1 (0.52) CYP2D6OPRK1LMNAHDAC4HDAC1
SCHEMBL22468482 0.84 SRD5A2 (0.47)
SCHEMBL15359365 0.84 OPRK1 (0.47) CYP2D6SRCOPRK1LMNAMAPK1
SCHEMBL10402082 0.84 OPRK1 (0.44) CYP2D6SRCOPRK1LMNAMAPK1
SCHEMBL8645113 0.84 OPRK1 (0.44) CYP2D6SRCOPRK1LMNAMAPK1
SCHEMBL12174989 0.84 OPRK1 (0.47) CYP2D6SRCOPRK1LMNAMAPK1
SCHEMBL11503746 0.84 SRC (0.47) CYP2D6SRCOPRK1KMT2ANAALAD2
SCHEMBL10402081 0.84 OPRK1 (0.44) CYP2D6SRCOPRK1LMNAMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110177783-A Hormone receptor modulators for the treatment of metabolic conditions and disorders 阿德利克斯股份有限公司 2019-08-27 CN claimed
US-12384810-B2 Organometallic compound and light-emitting device including organometallic compound SAMSUNG DISPLAY CO., LTD. (KR) 2025-08-12 US disclosed
WO-2023020789-A1 METHODS FOR PREPARING OXAZABOROLIDINES PATHWAY INTERMEDIATES LIMITED (GB) 2023-02-23 WO disclosed
WO-2023020789-A1 METHODS FOR PREPARING OXAZABOROLIDINES PATHWAY INTERMEDIATES LIMITED (GB) 2023-02-23 WO disclosed
US-20220246868-A1 ORGANOMETALLIC COMPOUND AND LIGHT-EMITTING DEVICE INCLUDING ORGANOMETALLIC COMPOUND SAMSUNG DISPLAY CO., LTD. (KR) 2022-08-04 US disclosed
CN-110177783-A Hormone receptor modulators for the treatment of metabolic conditions and disorders 阿德利克斯股份有限公司 2019-08-27 CN disclosed
CN-102976970-B Preparation method of isocyano compound UNIV NANJING SCIENCE & TECH 2014-12-17 CN disclosed
EP-2435433-B1 (DIHYDRO)IMIDAZOISO[5,1-A]QUINOLINES AS FSH RECEPTOR AGONISTS FOR THE TREATMENT OF FERTILITY DISORDERS MERCK SHARP & DOHME (NL) 2013-08-28 EP disclosed
US-8071587-B2 (Dihydro)imidazoiso[5,1-A]quinolines N. V. ORGANON (NL) 2011-12-06 US disclosed
US-8071587-B2 (Dihydro)imidazoiso[5,1-A]quinolines N. V. ORGANON (NL) 2011-12-06 US disclosed
US-20100324021-A1 (DIHYDRO)IMIDAZOISO[5,1-A]QUINOLINES N.V. ORGANON (NL) 2010-12-23 US disclosed
WO-2010136438-A1 (DIHYDRO) IMIDAZOISO (5, 1-A) QUINOLINES AS FSH RECEPTOR AGONISTS FOR THE TREATMENT OF FERTILITY DISORDERS N.V. ORGANON (NL) 2010-12-02 WO disclosed
WO-2010136438-A1 (DIHYDRO) IMIDAZOISO (5, 1-A) QUINOLINES AS FSH RECEPTOR AGONISTS FOR THE TREATMENT OF FERTILITY DISORDERS N.V. ORGANON (NL) 2010-12-02 WO disclosed
EP-1924551-A2 ORGANIC COMPOUNDS Novartis Pharma AG (CH) 2008-05-28 EP disclosed
WO-2007025709-A2 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2007-03-08 WO disclosed
EP-0775110-A1 ARYLTHIO COMPOUNDS AS ANTIBACTERIAL AND ANTIVIRAL AGENTS WARNER-LAMBERT COMPANY (US) 1997-05-28 EP disclosed
WO-1996004242-A1 ARYLTHIO COMPOUNDS AS ANTIBACTERIAL AND ANTIVIRAL AGENTS WARNER-LAMBERT COMPANY (US) 1996-02-15 WO disclosed
US-5232978-A 1-(2-arylethyl)-pyrrolidines MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 1993-08-03 US disclosed
US-3996216-A 3-Heterothio derivatives of (formylamino)acetylamino-7-alpha-methoxy cephalosporins E. R. SQUIBB & SONS, INC. (US) 1976-12-07 US disclosed
US-3949079-A PLEUROMUTILIN; BACTERICIDES IN ANIMAL FEEDS BIOCHEMIE GES.M.B.H. (OE) 1976-04-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100324021-A1 (DIHYDRO)IMIDAZOISO[5,1-A]QUINOLINES NQO2, IPO5, SCN5A CYP2D6 306/4885SRC 4146/4885OPRK1 1089/4885
US-20220246868-A1 ORGANOMETALLIC COMPOUND AND LIGHT-EMITTING DEVICE INCLUDING ORGANOMETALLIC COMPOUND LEF1, CRY1, DDT CYP2D6 256/4885SRC 3443/4885OPRK1 3229/4885
US-12384810-B2 Organometallic compound and light-emitting device including organometallic compound LEF1, CRY1, DDT CYP2D6 256/4885SRC 3443/4885OPRK1 3229/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.